summari report result increas
ep estim penni in-lin
consensu sale estim increas
organ also in-lin consensu estim
analysi iqvia data suggest strength sever us
drug see pharma tracker start page thu
increas total revenu forecast net
includ modest improv fx headwind turn
see jnj sale growth acceler modestli expect
initi guidanc conserv expect manag
guid organ sale growth report ep
ex-fx forecast total revenu
organ growth ep compar consensu
respect strateg expect
continu de-emphas consum busi
increas price target base
updat sum-of-th part analysi impli
ep estim
iqvia analysi suggest strong us pharma perform
expect growth deceler across three key
segment forecast total sale organ
sale growth repres deceler growth
ytd part due benefit rebat adjust
inventori stock prior quarter
see deceler due increas biosimilar/gener sale eros
increas us pharma sale forecast nearli
net base analysi iqvia data medic devic
expect revers buy-in benefit japan vision depress
growth consum nielsen data analysi suggest
forecast may conserv earli start flu season
repres potenti increment tailwind quarter
expect introduc conserv guidanc
start year base busi momentum exit last year
expect guid organ sale growth
would direct consist guidanc
top-lin growth forecast total revenu
organ growth report ahead consensu
model assum slight yr/yr growth acceler
three key busi forecast ep
consensu reflect approxim declin net
incom guidanc slight fx headwind expect
introduc ep guidanc year
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani data secur llc estim reuter
expect sale growth deceler three busi report result
rais ep estim penni consensu forecast
also increas total revenu forecast net adjust organ
growth also in-lin consensu expect top-lin increas larg reflect stronger-than-
expect iqvia trend sever key us drug slight decreas fx pressur
estim organ sale growth includ estim
prior period true benefit us concerta zytiga exclud true
growth deceler modest reflect increas impact us biosimilar remicad procrit
gener competit zytiga tracleer consum estim organ growth
assum deceler forecast appear bit conserv compar
nielsen data earli start flu season may give boost jnj over-the-counter perform medic
devic model organ sale growth growth includ
sever one-tim benefit japan buy-in ahead consum tax hike trauma rebat adjust etc
assum growth somewhat depress revers japan buy-in benefit
adjust factor quarter growth deceler modest
iqvia data point stronger expect perform sever key us drug base
iqvia analysi rais us sale forecast darzalex imbruvica stelara tremfya
nearli aggreg partli off-set lower sale estim zytiga tracleer
uptravi total chang sale forecast us remicad xarelto estim
iqvia analysi point potenti upsid although magnitud potenti upsid
appear modest note continu biosimilar eros remicad procrit
gener eros zytiga tracleer creat uncertainti potenti adjust captur
iqvia inventori prior period price adjust etc forecast us pharmaceut sale
yr/yr growth in-lin report organ growth
detail product tracker analysi start page
earli start flu season may give slight boost consum sale growth jnj ww
consum sale grew ytd expect ww consum organ sale growth
slower due tougher yr/yr comp analysi aggreg nielsen data
point slight uptick us consum growth better assumpt
deceler us consum sale growth due tougher yr/yr comp
figur howev growth forecast may prove bit conserv given earlier start flu
season year could boost jnj over-the-counter busi nielsen data appear trend direct in-lin
report us consum sale growth time notabl quarterli variat part
due quarterli calcul use weekli nielsen data figur ww basi forecast
consum sale organ growth includ us sale
organ growth ex-fx compani report secur llc estim organ growth adjust fx acquisitions/divestitur sell day prior price adjust pharma venezuela anima exit pharma overal growth adjust remicad rebat ex-adjust organ growth pharma overal cardiovascular cerenovu neurovascular intervent solut start diabet adjust anima exit impact vision growth adjust stock destock associ consumpt tax hike japan note amo acqusit includ ex-fx growth rate atln acquisit includ ex-fx growth rate key busi segment johnson johnson
nielsen sale base aggreg data
nielsen sale base aggreg data
summari outlook
see slight acceler organ sale growth expect slightli improv sale growth
jnj three key busi segment believ posit growth momentum
jnj underli busi last year continu year help diminish headwind
generic/biosimilar competit new product launch forecast total revenu
ahead consensu forecast forecast assum underli growth small
improv estim give guidanc anticip manag
guid conserv underli sale growth start year report basi
estim currenc headwind reduc report sale growth
pharmaceut growth expect continu outpac market expect pharma sale
growth continu outpac market growth compani see view
realist goal forecast stabl underli pharma growth vs estim
would consist jnj underli sale growth averag
call manag note pharma sale growth
depend part perform may reflect steeper generic/biosimilar eros creat easier
comp continu modest eros recal impact loe loss exclus
gener zytiga less expect guidanc estim impact lower
like make bit difficult significantli acceler pharma growth
medic devic growth maintain posit momentum analyst day
target improv medic devic sale growth reach above-market
growth compani done good job past month move toward goal
busi divest new launch manag expect busi grow line
market see realist goal current forecast organ sale growth
compar estim
consum growth improv somewhat market expect broader consum
market grow estim growth compani expect
consum sale growth competit market suggest uptick estim
below-market growth sens may de-emphasize consum busi
continu narrow focu area like beauti over-the-counter over-the-count investor
confer jan head consum busi absent line-up ashley mcevoy evp
world-wide chairman medic devic jennif taubert evp world-wide chairman
expect focu portfolio optim within consum would consist
histori prune under-perform asset clear path improv
net incom expect declin manag expect net incom
half guidanc estim repres ep impact
drag earn growth recal net incom includ gain
divestitur asp similar size deal current contempl expect
net incom still assum divestitur believ compani alreadi
level set expect earn call
estmkt compani report secur llc organ growth report ex-fx adjust sell day differ venezuela impact prior period price adjust sale guidanc mm lowmidhighour report sale organ growth oper fx headwind report report compani report factset secur llc estim report organ growth defin ex-fx johnson johnson
histori suggest abl manag expect net incom declin
declin reduc earn growth see potenti offset improv
oper leverag lower share count estim margin increas larg
consum segment realist potenti off-set addit complet share buy-back
add estim ep growth recal although jnj net incom fell
gain sale nucynta cordi compani ep still grew nearli
help nearli oper margin leverag slight reduct fx headwind
small tax benefit magnitud declin incom margin expans
expect modest vs believ histori support jnj abil manag
volatil
ep growth expect in-lin sale growth typic target
grow ep faster sale year challeng due headwind lower net
incom discuss call manag comment ep growth expect
around sale growth unlik eps/sal growth ratio expect expect
improv sale growth sg leverag partli off-set lower net incom modest fx
headwind net-net see mid-singl digit report ep growth reason start point
would impli high-singl digit underli ep growth adjust fx declin net
incom buyback-driven share count reduct forecast report ep
growth ex-fx give guidanc expect compani start conserv
usual see like report ep rang growth
addit share buy-back possibl complet share repurchas littl less
year first announc estim share count reduct add
annual jnj ep ep growth els equal new stock
buy-back program announc see possibl given jnj strong cash
posit cash end current forecast assum materi addit share
buy-back
epslowmidhighour report ep adjust oper adjust oper declin net oper oper fx report ep compani report factset secur llc estim includ annual benefit share buy-back complet chang tailwind tw headwind hw increas hw becam plu tax chang hw tw tw decreas hw increas compani report secur llc estim repres initi compani guidanc repres midpoint guidanc rang ep growthreport ep medic technolog
encourag updat talc opioid litig could see talc litig remain
overhang much mostli proceed case-by-cas basi far howev
larg analysi nih nation institut publish jama journal american medic
associ jan found evid link babi powder ovarian cancer case
pend relat talc-contain bodi powder understand major
ovarian cancer case believ public posit compani next
key event talc litig decis daubert hear held juli
expect day judg expect decid whether plaintiff reliabl scientif proof
regard talc-ovarian cancer link opioid case believ recent updat ok
oh support view damage/settl like manag given strong
balanc sheet recal order pay ok case vs request
plaintiff settl oh case without admiss liabil compani current
await process settlement stage could happen
sale yr/yr declin compar qtd oct-nov iqvia sale declin
yr/yr direct report us remicad sale declin sever iqvia sale
declin recent quarter exampl report us remicad sale fell yr/yr
compar iqvia sale declin period forecast declin
biosimilar remicad penetr continu climb iqvia sale show biosimilar remicad
sale continu inch ytd iqvia sale total oct compar jan
figur growth biosimilar remicad sale driven
pfe/celltrion inflectra mrk renflexi meanwhil trail averag remicad iqvia sale
fallen earlier year appear direct
consist eros report sale due increas rebat discount iqvia sale show
inflectra account biosimilar remicad iqvia sale share
start year
biosimilar procrit uptak remain ahead biosimilar remicad first year sale pfe
biosimilar procrit retacrit launch appear ramp faster initi biosimilar
remicad launch first year specif iqvia sale show retacrit sale
decemb time jnj procrit iqvia sale fallen
respect forecast us procrit sale
yr/yr compar declin ytd forecast seem reason base
extrapol iqvia sale
spravato balversa sale appear mostli track new spravato indic expect
receiv fda approv spravato treatment resist depress balversa
bladder cancer earli spravato distribut limit physician must certifi
prescrib drug limit iqvia data extrapol iqvia sale spravato total
slightli us estim spravato trx averag per week recent
averag per week june file spravato label expans includ rapid
reduct depress symptom patient suicid ideat believ clinic data warrant
fda approv especi given lack treatment option would view new indic
increment growth driver spravato start spravato grant breakthrough therapi
design indic suggest fda approv could sooner balversa extrapol
iqvia sale total slightli estim given spravato balversa
limit distribut continu monitor assess well iqvia data captur actual sale
iqvia suggest modest upsid us darzalex sale forecast share gain continu
line use rais us darzalex sale forecast increas
yr/yr base extrapol iqvia sale ww basi forecast darzalex sale
total ex-fx growth yr/yr forecast ww darzalex sale in-
line genmab estim darzalex approv front-lin use us
transplant elig inelig patient could help acceler sale growth
addit expect fda approv subq darzalex formul expect repres
anoth potenti growth tailwind year accord brandimpact darzalex share front-lin mm
multipl myeloma rose aug follow front-lin maia
cassiopeia approv jun sep line use darzalex share reach
oct one share point behind market leader revlimid figur line mm darzalex
share tie lead pomalyst figur darzalex share overal mm market
doubl past year nearli brandimpact survey
increas us imbruvica sale forecast rais us imbruvica revenu
estim impli end-us sale
within extrapol iqvia sale rang impli revenu
ww imbruvica revenu forecast increas amount
translat revenu rx perspect roll
imbruvica volum grew weekli exce figur call note
imbruvica remain clear market leader cll across line therapi
us invokana sale forecast appear reason estim us invokana sale
declin yr/yr in-lin extrapol iqvia sale invokana
franchis volum fell oct/nov consist ytd perform suggest possibl
stabil franchis figur iqvia data first three week show similar yr/yr
rx volum declin rang figur invokana franchis nrx share class
also remain rel stabl mid-teen recent month competitor boehring ingelheim
lli jardian franchis remain leader categori nrx share nearli
nrx volum growth figur recal jardianc empa-reg outcom trial show
drug lower cardiovascular risk without increas amputation/fractur risk categori nrx
growth averag ytd compar growth
us zytiga sale estim in-lin iqvia data us gener zytiga competit began
decemb initi impact benign anticip zytiga sale fall
yr/yr compar typic gener eros slower sale eros like least
partli attribut strong perform jnj generiz zytiga held share
closest competitor apotx averag share extrapol iqvia sale
suggest us zytiga sale rang consist estim
declin yr/yr comparison brand zytiga trx nrx volum
respect to-dat jnj gener zytiga rx volum continu climb
erleada uptak continu measur pace nearli year sinc launch erleada us sale
annual nearli base iqvia sale annual iqvia sale
start monthli erleada trx nrx volum increas slowli estim
us erleada sale slightli extrapol iqvia sale quarter
chang forecast given small magnitud differ erleada label expand late
includ metastat castration-sensit prostat cancer mcspc help broaden
adopt
maintain xarelto sale forecast although upsid possibl estim us xarelto
sale declin yr/yr forecast extrapol iqvia sale
note differ report iqvia sale widen past month possibl
due increas discounting/reb competit market weve found histor
iqvia/report sale ratio less reliab forecast thu chang estim
although cad/pad coronari arteri disease/peripher arteri diseas indic contribut
posit franchis growth overal xarelto rx volum growth deceler averag
low-singl digit rang figur iqvia trend suggest xarelto cad/pad
ad overal xarelto franchis growth recent month competitor eliqui
maintain lead among noac share m/m follow xarelto
share m/m past year xarelto lost share eliqui gain
share figur noac account oral anticoagul nrx two year ago
figur oct fda approv xarelto use cad/pad coronari arteri disease/peripher
lower us invega sustenna/trinza sale forecast lower us stelara/trinza sale
estim would fall within extrapol iqvia sale rang
new estim still high-end iqvia extrapol rang note
report stelara/trinza sale exceed iqvia sale last coupl quarter specif jnj
growth differ meaning iqvia sale growth report vs iqvia
report vs iqvia figur comfort growth
assumpt vs iqvia sale growth remain unclear us chang
iqvia calcul data sourc may depress sale jnj laia franchis apr-oct
result yr/yr sale declin vs histor growth high-singl double-digit us laia
market maintain lead franchis nrx market share past
month ostuka abilifi maintena hold share yr/yr aristada share
increas us stelara sale forecast increas us stelara sale
yr/yr growth within extrapol iqvia sale rang note
tougher yr/yr comp report us stelara sale growth stelara iqvia sale grew
oct/nov point growth deceler exit
year perhap due strong uptak tremfya figur stelara fda approv
ulcer coliti uc oct repres growth tailwind drug eu approv
sep stelara trx volum specialti continu show crohn key growth driver
nearli growth volum written gastroenterolog specialist past year partli
off-set declin volum written dermatologist dermatologist account
stelara vs start write vs earli
expect mix gi-written stelara rx continu increas uptak new uc
indic also treat
increas us tremfya sale forecast rais us tremfya sale
base extrapol iqvia sale rang report sale track
rel consist iqvia sale sinc launch littl year market tremfya
iqvia sale annual base oct/nov data comparison nv cosentyx
lli taltz sale annual respect time post-launch current
cosentyx iqvia sale annual taltz iqvia sale annual weekli
tremfya trx volum continu track ahead stelara remain behind cosentyx taltz
time post-launch figur believ tremfya remain key growth driver
sun pharma ilumya seen limit commerci traction month post launch
maintain us simponi/aria sale estim forecast us simponi/aria sale
direct consist extrapol iqvia sale forecast
impli growth yr/yr slightli ytd growth oct/nov simponi iqvia
sale fell yr/yr aria iqvia sale nearli togeth drive franchis growth
lower us tracleer uptravi sale forecast decreas us tracleer sale
estim half in-lin extrapol iqvia sale
quarter chang forecast take account materi chang addit discount
rebat accrual inventori adjust due gener eros uptravi lower us
forecast bring number in-lin extrapol iqvia
sale opsumit us sale estim slightli extrapol
iqvia sale rang figur note greater variabl
report sale iqvia sale vari quarter quarter product pah pulmonari
arteri hypertens franchis compar product track via iqvia
analysi independ arriv secur llc basi data
inform iqvia respons relianc recipi either data analys
estim us split iqvia nation sale perspect compani report secur llc estim sale estim base commentari iqvia data forecast us imbruvica sale assum record end-us sale report consist third month perform prior quarter assum decemb im sale repres medic technolog
compris mostli pfe/celltrion inflectra
figur darzalex tie posit line multipl myeloma market
figur darzalex tie lead line multipl myeloma market
follow chang imbruvica ndc nation drug code iqvia report doubl count rx
one distributor late march continu part year
rxtrxnrxfeb cll approvedmar front-lin cll approvedjul r/r cll label expans includ mutat jan waldenstrm macroglobulinemia approvedaug graft-vs-host-diseas cgvhd growthmonthli trxtrx volumetrx rx y/i present canva data ada meet -posit efficaci safeti trade-off strengthen warn risk acut kidney add black box warn leg foot amput risk medic technolog
figur invokana franchis continu lose share
figur zytiga erleada monthli volum growth trend
new oral anticoagul includ pradaxa xarelto eliqui savaysa
growth trxtrx growthtrx nrxnrxoral anticoagulantsnew oral anticoagul new oral anticoagul xarelto spaf approvedeliqui spaf approvedsavaysa spaf approvedeliqui dvt treatment approvedxarelto dvt treatment approvedeliqui dvt prevent approv medic technolog
growthim sale sustenna trinza consta sale yoy im sale growthsustenna launch aug launch jun market sharealk aristadaotsuka abilifi maintenajnj sinvega sustenna trinza risperd growthsal stelara tremfya salesstelara tremfya yoy growthtremfya launch jul launch may crohn launch sep launch jan johnson johnson
figur atln opsumit iqvia sale maintain growth momentum
figur atln tracleer iqvia sale declin
figur atln uptravi iqvia sale remain solid launch trajectori
price target
price target impli cash ep base sum-of-the-part
analysi risk includ delay pipelin product unexpect delay deal integr unexpect
deterior industri
expect growth improv exit eas multipl headwind new
johnson johnson world comprehens broadli base healthcar compani
consum pharmaceut medic devic market medic devic segment consist primarili
product intervent orthoped surgic vision compani report sale
year-over-year organ basi
sale trxtrxim salesstart gener sale trxtrxim sale johnson johnson
